

14<sup>th</sup> December, 2017

To  
The General Manager,  
Department of Corporate Services,  
The BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, M Samachar Marg, Fort  
Mumbai, Maharashtra 400001

Dear Sirs / Madam

**Sub: Outcome of the Board Meeting held today & Submission of Un-Audited Financial Results for the 2nd quarter and half year ended 30<sup>th</sup> September, 2017.**


**Ref: BSE Scrip Code: VENMAX/531015**

In compliance with Regulation 30 and Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed herewith the un-audited Financial Results of Venmax Drugs And Pharmaceuticals Ltd for the 2<sup>nd</sup> quarter and half year ended September 30, 2017, as approved by the Board of Director at their meeting held today i.e. 14<sup>th</sup> December, 2017 at 4.00 P M and concluded at 4.50 PM.

You are requested to take the same on record and acknowledge.

Thanking you.

Yours faithfully  
For Venmax Drugs And Pharmaceuticals Ltd

  
Nuka Venkat Narender  
Managing Director  
DIN: 01641941



# VENMAX

DRUGS AND PHARMACEUTICALS LIMITED.

## VENMAX DRUGS AND PHARMACEUTICALS LIMITED

Registered Office: Nama Chemical Industries, Shed No.22, Plot No.84, Phase-I,

IDA Cherlapally, Hyderabad, Telangana - 500051 INDIA

CIN:L24230TG1988PLC009102

Statement of Audited Financial Results for the Quarter Ended 30th September, 2017

		(Rs. In Lacs)					
S No.	PARTICULARS	Quarter ended	Quarter ended	Quarter ended	Half year ended	Nine Months ended	Year Ended
		30.09.2017	30.06.2017	30.09.2016	30.09.2017	30.09.2016	31.03.2017
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>1</b>	<b>Income from Operations</b>						
	a) Net Sales/ Income from Operations	0.00	0.00	8.66	0.00	25.92	25.92
	b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	12.48
	<b>Total Income from Operations</b>	<b>0.00</b>	<b>0.00</b>	<b>8.66</b>	<b>0.00</b>	<b>25.92</b>	<b>38.40</b>
<b>2</b>	<b>Expenses</b>						
	a) Cost of material consumed						
	b) Purchase of stock-in-trade	0.00	0.00	7.88	0.00	24.42	24.42
	c) Changes in stock-in-trade and Work in Progress and stock in trade	0.00	0.00	0.00	0.00	0.00	0.00
	d) Employees Cost	1.40	1.30	1.20	2.70	2.65	6.07
	e) Depreciation	0.00	0.00	0.00	0.00	0.00	0.00
	f) Other Expenditure (any item exceeding 10% of the total expenses relating to continuing operation to be shown separately)	2.24	0.37	3.62		3.86	57.02
	<b>Total Expenses</b>	<b>3.64</b>	<b>1.67</b>	<b>12.70</b>	<b>5.31</b>	<b>30.93</b>	<b>87.51</b>
<b>3</b>	Profit / (Loss) from Operations before Other Income, Finance cost & Exceptional Items	-3.64	-1.67	-4.03	-5.31	-5.00	-49.11
<b>4</b>	Other Income	0.00	0.00	0.00	0.00	0.00	0.00
<b>5</b>	<b>Profit / (Loss) before Finance cost &amp; Exceptional Items</b>	<b>-3.64</b>	<b>-1.67</b>	<b>-4.03</b>	<b>-5.31</b>	<b>-5.00</b>	<b>-49.11</b>
<b>6</b>	Finance cost	0.00	0.00	0.00	0.00	0.00	0.00
<b>7</b>	Profit / (Loss) from ordinary activities after finance costs but before exceptional items	-3.64	-1.67	-4.03	-5.31	-5.00	-49.11
<b>8</b>	Exceptional Items	0.00	0.00	0.00	0.00	0.00	84.48
<b>9</b>	Profit / (Loss) from Ordinary activities before tax after tax	-3.64	-1.67	-4.03	-5.31	-5.00	-133.59
<b>10</b>	Tax Expenses	0.00	0.00	0.00	0.00	0.00	0.00
<b>11</b>	Net Profit / (Loss) from Ordinary Activities after Tax	-3.64	-1.67	-4.03	-5.31	-5.00	-133.59
<b>12</b>	Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
<b>13</b>	<b>Net Profit / (Loss) for the period</b>	<b>-3.64</b>	<b>-1.67</b>	<b>-4.03</b>	<b>-5.31</b>	<b>-5.00</b>	<b>-133.59</b>
<b>14</b>	Paid-Up Equity Share Capital (Face Value of Rs.10/-)	523.89	523.89	523.89	523.89	523.89	523.89
<b>15</b>	Reserves excluding Revaluation Reserves						-646.88
<b>16</b>	<b>Earning per share (EPS) (in Rs.) : (not Annualised)</b>						
	a) Basic and diluted EPS before Extraordinary Items	-0.07	-0.03	-0.08	-0.10	-0.10	-2.55
	b) Basic and diluted EPS after Extraordinary Items	-0.07	-0.03	-0.08	-0.10	-0.10	-2.55

1. The above results as reviewed by the Audit Committee were considered and approved by the Board of Directors at its meeting held on 14th December 2017.

2. Results for the quarter ended 30th September 2017 were subjected to limited review by the Auditors and their report contains
3. The results have been prepared in accordance with the Companies (Indian accounting standards) Rules, 2015 (Ind AS) and as per the provisions prescribed under section 133 of the Companies Act, 2013.
4. These results do not include Ind AS compliant results for the immediate preceding quarter and previous year ended 31st March 2017 as the same is not mandatory as per SEBI circular dated 5th July 2016.
5. Reconciliation of net profit for the corresponding previous quarter ended 30.09.2016 in accordance with Indian GAAP to the total comprehensive income.

Net profit under previous GAAP: -1.68

Ind AS adjustments : 0


Actuarial loss on employee defined benefit funds recognised in other comprehensive

Impact of current and differed taxes: 0

Net profit for the period under IND AS: -1.68

6. As the Company deals with single product i.e. Pharmaceuticals/ Machinery.

For Venmax Drugs and Pharmaceuticals



Managing Director

Place: Hyderabad

Date: 14.12.2017

## VENMAX DRUGS AND PHARMACEUTICALS LIMITED

Registered Office: Nama Chemical Industries, Shed No.22, Plot No.84, Phase-I,

IDA Cherlapally, Hyderabad, Telangana - 500051 INDIA

CIN:L24230TG1988PLC009102

Statement of Assets and Liabilities	As at	As at
	30 September 2017	30th September 2016
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	-	-
<i>Financial assets</i>		
(i) Investments	-	58,000
Deferred tax assets (net)	-	8,448,000
Other non current assets	1,156,308	10,051,000
	<b>1,156,308</b>	<b>18,557,000</b>
<b>Current assets</b>		
<i>Financial assets</i>		
(i) Trade receivables	6,408,296	6,820,000
(ii) Cash and cash equivalents	36,551	117,300
Other current assets	223,148	238,000
	<b>6,667,995</b>	<b>7,175,300</b>
	<b>7,824,303</b>	<b>25,732,300</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity share capital	52,389,300	52,389,300
Other equity	(65,220,007)	(50,804,000)
	<b>(12,830,707)</b>	<b>1,585,300</b>
<b>Non-current liabilities</b>		
<i>Financial Liabilities</i>		
(i) Borrowings	18,789,421	17,598,000
	<b>18,789,421</b>	<b>17,598,000</b>
<b>Current liabilities</b>		
<i>Financial Liabilities</i>		
(i) Trade payables	1,016,369	5,725,000
Other current liabilities	-	120,000
Provisions	849,220	704,000
	<b>1,865,589</b>	<b>6,549,000</b>
	<b>7,824,303</b>	<b>25,732,300</b>


### Summary of significant accounting policies

The accompanying notes are an integral part of the standalone financial statements.

For and on behalf of the Board of Directors of  
Venmax Drugs and Pharmaceuticals Limited

Place: Hyderabad

Date: 14.12.2017

  
Managing Director



Mobile  
(0) 92465 85998

Email  
madhufca@yahoo.com

Phone  
+91 40 2473 4994

## Independent Auditor's Review Report on Quarterly Financial Results of the Company

To the Board of Directors of Venmax Drugs and Pharmaceuticals Limited

### Introduction

We have reviewed the accompanying statement of unaudited financial results (standalone) ("the Statement") of Venmax Drugs and Pharmaceuticals Limited ("the Company") for the quarter and six months ended September 30, 2017, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulation, 2015"). This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.


### Scope of Review

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

### Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement has not been prepared, in all material respect, in accordance with applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in term of Regulation 33 of the Listing Regulation, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad.  
Date: 14/12/2017



For MADHU & ASSOCIATES  
Chartered Accountants  
Firm Reg. No. 001914S  
*M. Madhusudan*  
(M. MADHUSUDAN)  
Proprietor  
M. No: 028200